RetroSense Therapeutics Raises $6M Series B

RetroSense Therapeutics a biotechnology company raises $6M in a Series B financing.

RetroSense Therapeutics is a biotechnology company that is developing a game-changing gene therapy to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved therapies to improve or restore vision in patients with these retinal degenerative conditions.

Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration. RetroSense is located in Ann Arbor, Michigan, a short drive from Wayne State University, where the approach was pioneered. RetroSense has secured exclusive, worldwide rights to relevant intellectual property from Wayne State University and Salus University.

RetroSense’s management team has commercial and scientific experience across all phases of drug development, as well as startup success. The Company operates virtually in order to secure top industry talent for its diverse, specialized needs in an efficient and effective manner.

RetroSense is an agile company with a culture of flexibility, determination, and innovative thinking.

Share this post